0001683168-18-002170.txt : 20180808 0001683168-18-002170.hdr.sgml : 20180808 20180808074149 ACCESSION NUMBER: 0001683168-18-002170 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20180731 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180808 DATE AS OF CHANGE: 20180808 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PRECISION OPTICS CORPORATION, INC. CENTRAL INDEX KEY: 0000867840 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 042795294 STATE OF INCORPORATION: MA FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-10647 FILM NUMBER: 18999826 BUSINESS ADDRESS: STREET 1: 22 EAST BROADWAY CITY: GARDNER STATE: MA ZIP: 01440 BUSINESS PHONE: 978-630-1800 MAIL ADDRESS: STREET 1: 22 EAST BROADWAY CITY: GARDNER STATE: MA ZIP: 01440 FORMER COMPANY: FORMER CONFORMED NAME: PRECISION OPTICS Corp INC DATE OF NAME CHANGE: 20111027 FORMER COMPANY: FORMER CONFORMED NAME: PRECISION OPTICS CORPORATION INC DATE OF NAME CHANGE: 19930328 FORMER COMPANY: FORMER CONFORMED NAME: PRECISION OPTICS CORP INC DATE OF NAME CHANGE: 19600201 8-K 1 poci_8k-073118.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) July 31, 2018

 

PRECISION OPTICS CORPORATION, INC.

(Exact name of registrant as specified in its charter)

 

Massachusetts   001-10647   04-2795294
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)
         
22 East Broadway, Gardner, Massachusetts   01440
(Address of principal executive offices)   (Zip Code)

 

(978) 630-1800

(Registrant’s telephone number, including area code)

 

Not applicable.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 2.02        Results of Operations and Financial Condition.

 

On July 31, 2018, Precision Optics Corporation issued a press release announcing financial results for its fiscal quarter ended June 30, 2018. The full text of the press release is furnished as Exhibit 99.1. The information furnished in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that Section.

 

This report contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements related to our future activities or future events or conditions.  These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by our management.  These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict.  Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in our Annual Report on Form 10-K and in other documents that we file from time to time with the SEC.  Any forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

 

Item 9.01 Financial Statements and Exhibits.

 

99.1 Press Release issued by Precision Optics Corporation, Inc., dated July 31, 2018.  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Precision Optics Corporation, Inc.  
    (Registrant)
     
Date August 8, 2018    
     
    /s/ Joseph N. Forkey
   

Name: Joseph N. Forkey

Title: Chief Executive Officer

           

 

 

 

 

 

 

 

 

 

 

 2 

EX-99.1 2 poci_8k-ex9901.htm PRESS RELEASE

Exhibit 99.1

POCI_PMS301

 

 

 

PRECISION OPTICS CORPORATION

22 EAST BROADWAY

GARDNER, MASSACHUSETTS 01440-3338

Telephone 978 / 630-1800

Telefax 978 / 630-1487

 

 

 

NEWS RELEASE POC18-0063
FOR IMMEDIATE RELEASE Tuesday, July 31, 2018

 

Precision Optics Corporation, Inc. Announces Fourth Quarter 2018 Preliminary Revenue of $1.4 - $1.5 Million

 

GARDNER, MA, July 18, 2018. Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”), a leading developer and manufacturer of advanced micro-optical components used in next generation medical instruments, announced preliminary unaudited financial results for its fourth fiscal quarter, which ended on June 30, 2018. Revenues for the quarter were in the range of $1.4 to $1.5 million and operating income, gross of non-recurring items, is expected to be in the range of $100,000 to $200,000.

 

Commenting on the fourth quarter preliminary results, Joseph Forkey, Company CEO said, “In recent quarters we have described the anticipated transition of engineering programs, that we have worked on for a number of years, into production orders. We are extremely pleased with the preliminary results announced today, which reflect the successful start of some of these production orders along with increased production efficiencies. The sales pipeline continues to support on-going and new opportunities for the Company, and we expect revenue levels for the first quarter of fiscal 2019 to remain strong.

 

Dr. Forkey continued, “The level of revenue reported today is the highest in over twenty years for Precision Optics, and really represents a milestone for our company. Our shareholders have been patient and our employees have been steadfast in their commitment to the Company as we have worked with customers to design and build market-leading optical technologies and to manage them through the development process and into production. I am extremely proud of the Company and of all of our employees for reaching this milestone, and we look forward to building on this success.”

 

Quarterly Conference Call Details

In mid-September 2018 the Company will announce the date and call in numbers for its quarterly conference call to discuss the fiscal year 2018 fourth quarter and year end audited financial statements. The quarterly conference call is expected to take place on Friday, September 28, 2018.

 

About Precision Optics Corporation

Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982. Using proprietary optical technologies, the Company designs and produces next generation medical instruments, MicroprecisionTM micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems for a broad range of customers including some of the largest global medical device companies. The Company’s innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company believes that current advances in its proprietary micro-optics and 3D imaging technologies present significant opportunities for expanding applications to numerous potential medical products and procedures. The Company’s website is www.poci.com. Investors can find Real-Time Quotes and market information for the Company on www.otcmarkets.com/stock/PEYE/quote.

 

 

 

 1 

 

 

About Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this report, except as required by law.

 

Company Contact:

Precision Optics Corporation

22 East Broadway

Gardner, Massachusetts, 01440-3338

Telephone: 978-630-1800

 

Investor Contact:

PCG Advisory Group

Kirin M. Smith

Chief Operating Officer

Telephone: 646-863-6519

Email: Ksmith@PCGAdvisory.com

Website: www.PCGAdvisory.com

 

 

 

 

 

 

 

 

 

 2 

 

GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end